Evidence map›Paper›PMID 32295873›Full record

ArticlemSphere2020

Immunization with a Biofilm-Disrupting Nontypeable

Michael T Bailey, Christian L Lauber, Laura A Novotny, Steven D Goodman, Lauren O Bakaletz

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Recent advances in enterotoxin vaccine adjuvants.Current opinion in immunology · 2023
    Review
  6. Article
  7. Review
  8. NontypeableBiofilm · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael T Bailey *Center for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Christian L Lauber *Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Laura A NovotnyCenter for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Steven D GoodmanCenter for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Lauren O BakaletzCenter for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA Lauren.Bakaletz@nationwidechildrens.org.ORCID 0000-0002-0017-1710
Nationwide Children's Hospital · US

Funding

Novel immunotherapeutics for the management of otitis media due to H. influenzaeR01DC011818 · NIDCD · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BAKALETZ, LAUREN O, GOODMAN, STEVEN D · 2011 to 2020
$5.4M
NIDCD NIH HHS R01 DC011818
6 · The paper itself

Abstract

The use of broad-spectrum antibiotics to treat diseases, such as the highly prevalent pediatric disease otitis media (OM), contributes significantly to the worldwide emergence of multiple-antibiotic-resistant microbes, and gut dysbiosis with diarrhea is a common adverse sequela. Moreover, for many diseases, like OM, biofilms contribute significantly to chronicity and recurrence, yet biofilm-resident bacteria are characteristically highly resistant to antibiotics. The most cost-effective way to both prevent and resolve diseases like OM, as well as begin to address the problem of growing antibiotic resistance, would be via the development of novel approaches to eradicate bacterial biofilms. Toward this goal, we designed a vaccine antigen that induces the formation of antibodies that prevent biofilm formation and, thereby, experimental OM in the middle ears of chinchillas by the predominant Gram-negative pathogen responsible for this disease, nontypeable

Indexed as

Gastrointestinal MicrobiomeAdministration, OralAmoxicillin-Potassium Clavulanate CombinationAnimalsAnti-Bacterial AgentsAntibodies, BacterialAntigens, BacterialBiofilmsChinchillaCohort StudiesEar, MiddleFemaleHaemophilus InfectionsHaemophilus influenzaeHaemophilus VaccinesImmunizationAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsAntibodies, BacterialAntigens, BacterialHaemophilus VaccinesdmLTDNABIImicrobiomeotitis mediatip-chimer peptide

Identifiers

PMID32295873
PMCPMC7160684
OpenAlexW3017249066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.